InflaRx Secures €44M Grant From German Govt To Advance Its COVID-19 Trial

  • The German Ministry of Education & Research and the Ministry of Health have granted €43.7 million to InflaRx N.V. IFRX to support the development of vilobelimab for COVID-19 patients.
  • The grant was awarded as part of a government initiative, which the German Federal Government announced earlier this year, to accelerate the development of promising therapeutic options for treating COVID-19 in patients at all stages of the disease.
  • The initial tranche of €25.8 million (approximately $29.9 million) is structured as reimbursement of 80% of certain pre-specified expenses related to the clinical development and manufacturing of vilobelimab. 
  • The remainder of the grant will be awarded in three additional tranches, each conditional on reaching agreed-upon development and manufacturing-related milestones. 
  • Payments from this grant to the Company are expected to begin in Q4 2021.
  • The Phase 3 part of Phase 2/3 study with vilobelimab in critically ill, mechanically ventilated COVID-19 patients has been fully enrolled. Top-line results are expected in Q1 of 2022.
  • Related: InflaRx's Vilobelimab Shows Encouraging Signs Of Drug Activity In Mid-Stage Study With Dermatological Ulcer Patients.
  • Price Action: IFRX shares are up 13.60% at $2.75 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechGovernmentLong IdeasNewsPenny StocksHealth CareFinancingMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusPhase 2 TrialPhase 3
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!